Objective
The 50% of women with dense breast tissue who are currently screened for breast cancer by mammography have large numbers of cancers missed, and non-cancerous features erroneously diagnosed, due to the difficulty of a mammogram distinguishing tumours from dense breast tissue. In dense breasts, around 1 in 2 cancers is missed by mammography.
Molecular Breast Imaging has much higher sensitivity (a better cancer detection rate) and specificity (fewer false alarms) than mammography, particularly for dense breasts. Its use as a screening technology is currently restricted due to its high radiation dose and inability to guide a biopsy.
This feasibility study will investigate the technical, economic and regulatory viability of Kromek’s technology to being adopted in optimised diagnosis pathways. Kromek currently supplies detectors into the MBI market, and have a number of innovative platform technologies to add to the current offering to create a system to address these barriers to adoption. Work in this Phase 1 study will identify the dose vs cancer detection balance, to guide the application of the technologies to the market needs.
We predict sales in the EU and USA of 147 million Euros in the first five years after commercialisation, which will help address the approximately 110 thousand women in Europe whose cancers in dense breasts are currently missed by mammography.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- social sciencessociologydemographymortality
- social scienceseconomics and businesseconomicsproduction economicsproductivity
- medical and health sciencesclinical medicineoncologybreast cancer
- social scienceseconomics and businesseconomicshealth economics
- natural sciencesphysical sciencesacousticsultrasound
You need to log in or register to use this function
Programme(s)
Topic(s)
Funding Scheme
SME-1 - SME instrument phase 1Coordinator
TS21 3FD Sedgefield Durham
United Kingdom
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.